Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

Krina K. Patel, Elisabet E. Manasanch, Hans C. Lee, J Christine Ye, Sheeba K. Thomas, Donna M. Weber, Melody R. Becnel, Mahmoud R. Gaballa, Hima Bansal, Zuzana Berkova, Sattva S. Neelapu, Cara L Haymaker, Minghao Dang, Linghua Wang, Greg Lizee, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 4737.

https://doi.org/10.1182/blood-2024-205663

Published: 2024

Journal Articles

Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2023-187583

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Minghao Dang, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Moreno Rueda, Mei Huang, David Berrios Nolasco, Hans C. Lee, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 89.

https://doi.org/10.1182/blood-2023-182902

Published: 2023

Journal Articles

Treatment and Coaching Experience of Individuals with Relapsed/Refractory Multiple Myeloma: Qualitative Insights during Treatment with Isatuximab

Kelly Brassil, Rahul Banerjee, Austin Barr, Trenton Grossfeld, Andrew J. Cowan, Elisabet E. Manasanch

Blood (2023) 142 (Supplement 1): 7439.

https://doi.org/10.1182/blood-2023-190950

Published: 2023

Journal Articles

Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit (CLPP) As a Novel Mediator of, and Target in High Risk Multiple Myeloma

Li Qin, Luz Yurany Moreno Rueda, Iqbal Mahmud, Isere Kuiatse, Wei Tan, Hans C. Lee, Krina K. Patel, David E. Symer, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 3302.

https://doi.org/10.1182/blood-2023-190766

Published: 2023

Journal Articles

Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience

Oren Pasvolsky, Michelle Hildebrandt, Naveen Subramanian, Christopher Ferreri, Hans C. Lee, Elisabet E. Manasanch, Sheeba K. Thomas, Donna M. Weber, Mahmoud Gaballa, Christen Dillard, Melody Becnel, Chitra Hosing, Pei Lin, Behrang Amini, Muzaffar H. Qazilbash, Nilesh Kalariya, Robert Z. Orlowski, Krina K. Patel

Blood (2023) 142 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2023-187854

Published: 2023

Journal Articles

Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM)

Hua Wang, Luz Yurany Moreno Rueda, Minghao Dang, Luz Yurany Moreno Rueda, Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Donna M. Weber, Elisabet E. Manasanch, David E. Symer, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 873.

https://doi.org/10.1182/blood-2023-189286

Published: 2023

Journal Articles

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4972.

https://doi.org/10.1182/blood-2023-189844

Published: 2023

Journal Articles

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2023-174558

Published: 2023

Journal Articles

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Blood (2023) 142 (Supplement 1): 4962.

https://doi.org/10.1182/blood-2023-174479

Published: 2023

Journal Articles

Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia

Szymon Szymura, Soungchul Cha, Lin Wang, Tiantian Zhang, Zhenyuan Dong, Aaron Anderson, Elizabeth Oh, Zhe Wang, Vincent Lee, Sapna Parshottham, Sheetal Rao, Jasper B Olsem, Brandon N Crumpton, Hans C. Lee, Elisabet E. Manasanch, Sattva S. Neelapu, Sheeba K. Thomas, Larry W. Kwak

Blood (2023) 142 (Supplement 1): 212.

https://doi.org/10.1182/blood-2023-182448

Published: 2023

Journal Articles

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Hans C. Lee, June Li, Heather Lin, Astrid D. Murga, Gabriela M Rodriguez, Mostafa E. Mohamed, Jared Henderson, Sarah Rodriguez, Melody R. Becnel, Donna M. Weber, Swami P. Iyer, Gregory P. Kaufman, Sheeba K. Thomas, Elisabet E. Manasanch, Krina K. Patel, Stephen J. Noga, Michael R. Green, Robert Z. Orlowski, Cara L Haymaker

Blood (2023) 142 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2023-188201

Published: 2023

Journal Articles

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2023-189109

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Luz Yurany Moreno Rueda, Keiko Akagi, Amishi U. Vora, Hans C. Lee, Krina K. Patel, Pei Lin, Bo Jiang, Yang Song, Maura L. Gillison, Sheeba K. Thomas, Donna M. Weber, Lixia Diao, Jing Wang, Elisabet E. Manasanch, David E. Symer, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 752.

https://doi.org/10.1182/blood-2023-188016

Published: 2023

Journal Articles

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Blood (2023) 142 (Supplement 1): 3764.

https://doi.org/10.1182/blood-2023-190882

Published: 2023

Journal Articles

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Hans C. Lee, Gregory P. Kaufman, Lei Feng, Astrid Murga, Ralph J. Johnson, Donna M. Weber, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Swaminathan P. Iyer, Krina Patel, Melody R. Becnel, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4428–4430.

https://doi.org/10.1182/blood-2022-167555

Published: 2022

Journal Articles

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Minghao Dang, Li Qin, Wei Tan, Liping Dong, Hans C. Lee, Krina Patel, Luz Yurany Moreno Rueda, Pei Lin, Hima Bansal, David Berrios, Sheeba K Thomas, Donna M. Weber, David E. Symer, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 7122–7124.

https://doi.org/10.1182/blood-2022-165540

Published: 2022

Journal Articles

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Blood (2022) 140 (Supplement 1): 430–432.

https://doi.org/10.1182/blood-2022-167390

Published: 2022

Journal Articles

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies

Kelly S. Chien, Christine B. Peterson, Elliana Young, Dai Chihara, Elisabet E. Manasanch, Jeremy L. Ramdial, Philip A. Thompson

Blood (2022) 140 (Supplement 1): 10938–10939.

https://doi.org/10.1182/blood-2022-169993

Published: 2022

Journal Articles

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Katherine Weissler, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Hao-Wei Wang, Constance M. Yuan, David F. Stroncek, Steven Highfill, Micaela Ganadan, Rashmika Patel, Steven A Rosenberg, James N. Kochenderfer

Blood (2022) 140 (Supplement 1): 7433–7434.

https://doi.org/10.1182/blood-2022-159156

Published: 2022

NARROW

Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Treatment and Coaching Experience of Individuals with Relapsed/Refractory Multiple Myeloma: Qualitative Insights during Treatment with Isatuximab

Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit (CLPP) As a Novel Mediator of, and Target in High Risk Multiple Myeloma

Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience

Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM)

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only